YUAN ZHAO: Open Payments
NPI 1679122592 · EL SEGUNDO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,485 in 97 payments from 22 companies in 2025. Trend: 2023 $891 · 2024 $1,651 · 2025 $2,485
Food & beverage: $2,400Education: $85
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $345 |
| Ascendis Pharma Endocrinology Inc | 11 | $335 |
| Amgen Inc. | 6 | $262 |
| Ascensia Diabetes Care Us Inc. | 15 | $189 |
| Lilly USA, LLC | 7 | $182 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $170 |
| Averitas Pharma Inc. | 5 | $158 |
| Novartis Pharmaceuticals Corporation | 4 | $129 |
| Mannkind Corporation | 3 | $110 |
| Tandem Diabetes Care, Inc. | 4 | $109 |
Products named: Yorvipath, JARDIANCE, Wegovy, MOUNJARO, QUTENZA, Ozempic, LEQVIO, REPATHA.
Industry payments across CA — which companies pay providers there.
